Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Suite E4622, Baltimore, MD 21205, USA.
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):605-13. doi: 10.1586/erp.12.52.
The biological basis for male contraception was established decades ago, but despite promising breakthroughs and the financial burden men increasingly bear due to better enforcement of child support policies, no viable alternative to the condom has been brought to market. Men who wish to control their fertility must rely on female compliance with contraceptives, barrier methods, vasectomy or abstinence. Over the last 10 years, the pharmaceutical industry has abandoned most of its investment in the field, leaving only nonprofit organisations and public entities pursuing male contraception. Leading explanations are uncertain forecasts of market demand pitted against the need for critical investments to demonstrate the safety of existing candidate products. This paper explores the developments and challenges in male contraception research. We produce preliminary estimates of potential market size for a safe and effective male contraceptive based on available data to estimate the potential market for a novel male method.
男性避孕的生物学基础早在几十年前就已确立，但尽管有前景看好的突破，以及由于更严格地执行子女抚养政策而导致男性承担的经济负担不断增加，但仍没有一种可行的避孕方法可以替代避孕套推向市场。那些希望控制生育能力的男性必须依靠女性遵守避孕药具、屏障方法、输精管切除术或禁欲。在过去的 10 年中，制药行业已经放弃了其在该领域的大部分投资，只剩下非营利组织和公共实体在追求男性避孕。主要的解释是，对市场需求的不确定预测与对现有候选产品的安全性进行关键投资的必要性相冲突。本文探讨了男性避孕研究的发展和挑战。我们根据现有数据对一种安全有效的男性避孕药具的潜在市场规模进行了初步估计，以估算一种新型男性避孕方法的潜在市场。
